MoonLake Gets Support From FDA, EMA For Nanobody Sonelokimab Phase 3 Program

February 26, 2024 — 09:16 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Biotechnology company, MoonLake Immunotherapeutics (MLTX), Monday announced positive outcomes from its interactions with the U.S. Food and Drug Administration or FDA, and the E.U. European Medicines Agency or EMA about the Phase 3 program, named VELA, of Nanobody sonelokimab in hidradenitis suppurativa or HS.

Hidradenitis suppurativa is a chronic, inflammatory skin disease, where lumps develop in areas such as armpits, groin, and buttocks due to rubbing of skin.

VELA is expected to start in the second quarter of 2024 with 800 patients, where a single SLK dose of 120 mg will be compared to a placebo over 16 weeks. The primary endpoint will be read out by mid-2025.

Further, the company stated that the end-of-Phase 2 meeting with the FDA regarding the psoriatic arthritis program will be held in the second quarter of 2024, followed by the Phase 3 program in the fourth quarter of the same year.

In the pre-market activity, MoonLake's stock is trading at $52.99, up 1.81 percent on the Nasdaq.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

MoonLake Gets Support From FDA, EMA For Nanobody Sonelokimab Phase 3 Program

Tags

Latest Articles